Clinical trials: Finerenone
Primary Aldosteronism, Hypertension
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism
Primary aldosteronism (PA) is thought to be the most common secondary endocrine form of hypertension. Compared with patients with essential hypertension with similar blood pressure, patients with PA have significantly higher…
- Trial name
- NCT05814770
- Testing
- Finerenone, Spironolactone
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Kidney Transplantation Recipients, Proteinuria Patients
FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan
The goal of this clinical trial is to learn if Finerenone works to treat proteinuria patients after kidney transplantation. It will also learn about the safety of Finerenone.
- Trial name
- FINEPKT (NCT07356388)
- Testing
- Experimental Group, Control (Standard treatment)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- kewen Chen,MD
Heart Failure and Preserved Ejection Fraction, Atrial Fibrillation (AF)
Finerenone's Impact on Cardiac Electrical Stability in HFpEF
To evaluate the efficacy of finerenone in reducing the incidence of any electrical instability or arrhythmias in the form of new-onset atrial fibrillation or atrial flutter (AFF), atrial tachycardia, extrasystoles (premature…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Atrial Fibrillation (AF), Arrythmia
- Trial name
- NCT07866287
- Testing
- Finerenone
- Volunteers
- 100 people
- Sponsor
- Assiut University
Finerenone, IgA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited…
- Conditions
- Finerenone, IgA Nephropathy, Proteinuria, Safety Issues
- Trial name
- NCT06460987
- Testing
- Finerenone, RAS inhibitor, Immune Suppressant
- Where
- China
- Volunteers
- 245 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
The main purpose of this study is to learn how treatment with finerenone affects the urinary albumin-to-creatinine ratio (uACR), a marker of kidney health, over time in adults with type 2 diabetes and chronic kidney disease who…
- Trial name
- FINE-IMSS-MX (NCT07841015)
- Testing
- Finerenone
- Where
- Mexico
- Volunteers
- 800 people
- Sponsor
- Bayer
Primary Aldosteronism
Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism
- Trial name
- FAVOR (NCT06164379)
- Testing
- Finerenone, Spironolactone
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Kidney Disease, Type 2 Diabetes
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
This is an observational study, in which data from the past of people with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FLAMINGO (NCT05640180)
- Testing
- Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
- Where
- United States
- Volunteers
- 17,847 people
- Sponsor
- Bayer
Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)
Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
The goal of this clinical trial is to evaluate whether Finerenone and Empagliflozin, either alone or in combination, can delay the progression of renal function decline in patients at high risk for chronic kidney disease (CKD)…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
- Trial name
- EmFin-Nx (NCT06818305)
- Testing
- Finerenone (BAY 94-8862), Empagliflozin 10 mg
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jinling Hospital, China
Diabetic Kidney Disease
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3…
- Trial name
- NCT07155694
- Testing
- Finerenone 10 MG, Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington D.C. Veterans Affairs Medical Center
Diabetic Nephropathy
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline.
- Trial name
- NCT07598864
- Testing
- Dapagliflozin +Finerenone arm, Dapagliflozin arm
- Where
- Bangladesh
- Volunteers
- 88 people
- Sponsor
- Chittagong Medical College
Heart Failure
Finerenone and Cardiac Remodeling
The goal of this clinical trial is to learn if the drug finerenone (Karendia) can improve heart function in participants who are at risk for heart and kidney disease.
- Trial name
- FINE-MECH (NCT07270367)
- Testing
- Finerenone
- Where
- 3 sites in Canada
- Volunteers
- 156 people
- Sponsor
- Subodh Verma
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
In this bioequivalence study, healthy male participants took the study treatment finerenone in the form of one and two tablets of different strengths by mouth.
- Trial name
- NCT07116512
- Testing
- Finerenone (BAY94-8862): intervention A, Finerenone (BAY94-8862): intervention B
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Membranous Nephropathy
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups.
- Trial name
- NCT06573411
- Testing
- ACEI/ARB+ finerenone, ACEI/ARB
- Where
- China
- Volunteers
- 116 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
CKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes…
- Trial name
- NCT07719621
- Where
- Spain
- Volunteers
- 100,000 people
- Sponsor
- Aeterna Medical Solutions SL
Diabetic Kidney Disease (DKD)
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease.
- Trial name
- NCT07348718
- Testing
- Kidney-Protective Therapies Used in Routine Care
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Rubix LS
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
- Trial name
- FINEXPLORER (NCT07554469)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Bayer
Primary Aldosteronism, Endocrine Hypertension
Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism
The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.
- Trial name
- NCT07688928
- Testing
- Finerenone
- Where
- Bangladesh
- Volunteers
- 104 people
- Sponsor
- Bangladesh Medical University
Heart Failure, Acute Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Trial name
- REDEFINE-HF (NCT06008197)
- Testing
- Finerenone
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 5,200 people
- Sponsor
- Colorado Prevention Center
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
This is an observational study in which data from people with chronic kidney disease (CKD) and Type 2 diabetes mellitus (T2D) are collected and studied.
- Trial name
- 22663 (NCT06608212)
- Testing
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Where
- United States
- Volunteers
- 238,038 people
- Sponsor
- Bayer